{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:02:09Z","timestamp":1764687729324,"version":"3.41.0"},"reference-count":167,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323527255"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/b978-0-323-52725-5.00016-2","type":"book-chapter","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T19:37:57Z","timestamp":1494617877000},"page":"307-326","source":"Crossref","is-referenced-by-count":6,"title":["Oral Administration of Nanoparticles-Based TB Drugs"],"prefix":"10.1016","author":[{"given":"Joana","family":"Magalh\u00e3es","sequence":"first","affiliation":[]},{"given":"Alexandre","family":"Vieira","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Pinheiro","sequence":"additional","affiliation":[]},{"given":"Salette","family":"Reis","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.02.009","article-title":"Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections","volume":"43","author":"Abed","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2228-5326-2-33","article-title":"Improved antimycobacterial activity of rifampin using solid lipid nanoparticles","volume":"2","author":"Aboutaleb","year":"2012","journal-title":"Int. Nano Lett."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jiph.2013.09.001","article-title":"Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis","volume":"7","author":"Ahmad","year":"2014","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2005.12.009","article-title":"Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses","volume":"27","author":"Ahmad","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijantimicag.2007.10.017","article-title":"Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole\u2014and moxifloxacin-loaded PLG nanoparticles","volume":"31","author":"Ahmad","year":"2008","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.femsle.2005.07.022","article-title":"In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv","volume":"251","author":"Ahmad","year":"2005","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1574-6968.2006.00350.x","article-title":"Azole antifungals as novel chemotherapeutic agents against murine tuberculosis","volume":"261","author":"Ahmad","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.nano.2007.05.001","article-title":"Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis","volume":"3","author":"Ahmad","year":"2007","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1128\/AAC.41.3.709","article-title":"Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes","volume":"41","author":"Aldridge","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/dna.2009.0874","article-title":"The oral microbiota: living with a permanent guest","volume":"28","author":"Avila","year":"2009","journal-title":"DNA Cell Biol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2013.08.037","article-title":"Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment","volume":"456","author":"Bagre","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0065","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1023\/A:1015885823793","article-title":"Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery","volume":"9","author":"Bai","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0009-3084(93)90071-A","article-title":"Liposomes: the Babraham connection","volume":"64","author":"Bangham","year":"1993","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cocis.2005.11.001","article-title":"Mucin structure, aggregation, physiological functions and biomedical applications","volume":"11","author":"Bansil","year":"2006","journal-title":"Curr. Opin. Colloid Interf. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin. Drug. Delivy"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0085","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/wnan.1333","article-title":"Mammalian gastrointestinal tract parameters modulating the integrity, surface properties, and absorption of food-relevant nanomaterials","volume":"7","author":"Bellmann","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0090","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejps.2013.03.008","article-title":"Nanocarrier systems for oral drug delivery: do we really need them?","volume":"49","author":"Bernkop-Schnurch","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/nano.2006.1.2.117","article-title":"Chitosan nanoparticles for oral drug and gene delivery","volume":"1","author":"Bowman","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF02956904","article-title":"The lipids of Mycobacterium tuberculosis BCG: fractionation, composition, turnover and the effects of isoniazid","volume":"3","author":"Brennan","year":"1970","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0169-409X(02)00044-3","article-title":"Nanoparticles in cancer therapy and diagnosis","volume":"54","author":"Brigger","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0115","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/03639040902774164","article-title":"Influence of the preparation procedure and chitosan type on physicochemical properties and release behavior of alginate-chitosan microparticles","volume":"35","author":"Cekic","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0120","first-page":"1","article-title":"Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design","volume":"10","author":"Chawla","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0125","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.addr.2012.10.010","article-title":"Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.resp.2004.10.003","article-title":"Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: implications for drug loaded surfactants","volume":"145","author":"Chimote","year":"2005","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.colsurfb.2011.05.025","article-title":"Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers","volume":"87","author":"Choonara","year":"2011","journal-title":"Colloids Surf."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0169-409X(00)00070-3","article-title":"Lectin-mediated mucosal delivery of drugs and microparticles","volume":"43","author":"Clark","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/07388551.2013.793649","article-title":"Glycosylation: impact, control and improvement during therapeutic protein production","volume":"34","author":"Costa","year":"2014","journal-title":"Crit. Rev. Biotechnol."},{"year":"1990","series-title":"Pharmacy: an illustrated history","author":"Cowen","key":"10.1016\/B978-0-323-52725-5.00016-2_bib0150"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0155","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/mabi.201000137","article-title":"Barrier properties of gastrointestinal mucus to nanoparticle transport","volume":"10","author":"Crater","year":"2010","journal-title":"Macromol. Biosci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1081\/DDC-100103730","article-title":"Preparation and physical characterization of alginate microparticles using air atomization method","volume":"27","author":"Cui","year":"2001","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1567201811666140716123050","article-title":"Inhaled dry powder formulations for treating tuberculosis","volume":"12","author":"Das","year":"2015","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0175","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.41.6.1211","article-title":"Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice","volume":"41","author":"Deol","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0278-6915(00)00136-8","article-title":"Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats","volume":"39","author":"DeSesso","year":"2001","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0185","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/jps.20875","article-title":"Role of nanotechnology in pharmaceutical product development","volume":"96","author":"Devalapally","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199937020-00003","article-title":"Pharmacokinetic factors in the modern drug treatment of tuberculosis","volume":"37","author":"Douglas","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/1568026033452537","article-title":"Fluoroquinolones: action and resistance","volume":"3","author":"Drlica","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"issue":"Suppl 1","key":"10.1016\/B978-0-323-52725-5.00016-2_bib0200","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/518137","article-title":"Pharmacokinetics and pharmacodynamics of antimicrobials","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1465-9921-7-118","article-title":"Tuberculosis chemotherapy: current drug delivery approaches","volume":"7","author":"du Toit","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0210","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/17425247.2014.846905","article-title":"State of the art and future directions in nanomedicine for tuberculosis","volume":"10","author":"Dube","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.drudis.2012.03.012","article-title":"Tuberculosis: from molecular pathogenesis to effective drug carrier design","volume":"17","author":"Dube","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0220","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1164\/ajrccm.161.4.16141","article-title":"Diagnostic standards and classification of tuberculosis in adults and children","volume":"161","author":"Dunlap","year":"2000","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0230","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0167-7799(97)01170-0","article-title":"Innovative strategies for the oral delivery of drugs and peptides","volume":"16","author":"Fasano","year":"1998","journal-title":"Trends Biotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0235","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1023\/A:1011925132473","article-title":"Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome)","volume":"15","author":"Fielding","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10611860410001693706","article-title":"Issues in oral nanoparticle drug carrier uptake and targeting","volume":"12","author":"Florence","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0245","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10611869509015936","article-title":"Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence","volume":"3","author":"Florence","year":"1995","journal-title":"J. Drug Target."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0250","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.tube.2015.05.017","article-title":"Tuberculosis: a disease without boundaries","volume":"95","author":"Fogel","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.colsurfb.2012.12.008","article-title":"Isoniazid loaded core shell nanoparticles derived from PLGA-PEG-PLGA tri-block copolymers: in vitro and in vivo drug release","volume":"104","author":"Gajendiran","year":"2013","journal-title":"Colloids Surf."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0260","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/198712b0","article-title":"Selective inhibition of nucleic acid synthesis in Mycobacterium tuberculosis by isoniazid","volume":"198","author":"Gangadharam","year":"1963","journal-title":"Nature"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0976-0016(12)60056-8","article-title":"Tuberculosis of the central nervous system","volume":"2","author":"Gauba","year":"2005","journal-title":"Apollo Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0270","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1164\/rccm.200504-613PP","article-title":"The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis","volume":"172","author":"Gelperina","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/tde.10.4","article-title":"Nanoparticulate strategies for effective delivery of poorly soluble therapeutics","volume":"1","author":"Gokce","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0280","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0378-5173(01)00915-2","article-title":"Alginate\/chitosan particulate systems for sodium diclofenac release","volume":"232","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0285","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejps.2005.04.009","article-title":"Microencapsulated chitosan nanoparticles for lung protein delivery","volume":"25","author":"Grenha","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0290","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrmicro2437","article-title":"Nanobead-based interventions for the treatment and prevention of tuberculosis","volume":"8","author":"Griffiths","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0295","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/bi00333a004","article-title":"Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles","volume":"24","author":"Gruner","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0300","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs","volume":"19","author":"Hamman","year":"2005","journal-title":"Biodrugs"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.vascn.2004.02.008","article-title":"Gastrointestinal-tract models and techniques for use in safety pharmacology","volume":"49","author":"Harrison","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/138161280302221006115933","article-title":"Inhibitors of ergosterol biosynthesis as antifungal agents","volume":"3","author":"Hartman","year":"1997","journal-title":"Curr. Pharm. Design"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0315","first-page":"889","article-title":"Update on latent tuberculosis infection","volume":"89","author":"Hartman-Adams","year":"2014","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0320","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4155\/tde.12.40","article-title":"Polymer-based oral peptide nanomedicines","volume":"3","author":"Herrero","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0325","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of tuberculosis","volume":"373","author":"Horsburgh","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","article-title":"Lipid nanocapsules: a new platform for nanomedicine","volume":"379","author":"Huynh","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0335","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0142-9612(94)90114-7","article-title":"Preparation and characterization of lectin-latex conjugates for specific bioadhesion","volume":"15","author":"Irache","year":"1994","journal-title":"Biomaterials"},{"year":"1998","series-title":"Fascinating hieroglyphics: discovering, decoding and understanding the ancient art","author":"Jacq","key":"10.1016\/B978-0-323-52725-5.00016-2_bib0340"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0345","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jconrel.2010.09.003","article-title":"Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug","volume":"148","author":"Jain","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0350","series-title":"Recent Advances in Novel Drug Carrier Systems","article-title":"Novel drug delivery systems for modulation of gastrointestinal transit time","author":"Javadzadeh","year":"2012"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0355","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0360","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MOG.0000000000000039","article-title":"The gut microbiota and the metabolic health of the host","volume":"30","author":"Joyce","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajps.2014.08.005","article-title":"Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs","volume":"10","author":"Junyaprasert","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0370","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Disp."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0375","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.immuni.2006.04.003","article-title":"Tuberculosis: back on the immunologists\u2019 agenda","volume":"24","author":"Kaufmann","year":"2006","journal-title":"Immunity"},{"year":"2005","series-title":"Essentials of Human Physiology for Pharmacy","author":"Kelly","key":"10.1016\/B978-0-323-52725-5.00016-2_bib0380"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0385","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1042\/cs0630187","article-title":"A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents","volume":"63","author":"Kerss","year":"1982","journal-title":"Clin. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2006.04.003","article-title":"Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion","volume":"113","author":"Kiptoo","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0395","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.colsurfa.2014.05.048","article-title":"Tuneable surface modification of PLGA nanoparticles carrying new antitubercular drug candidate","volume":"458","author":"Kiss","year":"2014","journal-title":"Colloids Surf."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0400","series-title":"Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance","article-title":"Old and New TB Drugs: Mechanisms of Action and Resistance","author":"Kolyva","year":"2012"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0405","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0924-8579(02)00175-9","article-title":"Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes","volume":"20","author":"Labana","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0410","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0415","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0022-3565(24)29290-9","article-title":"Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease","volume":"299","author":"Lamprecht","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0420","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4046\/trd.2015.78.2.47","article-title":"Diagnosis and treatment of extrapulmonary tuberculosis","volume":"78","author":"Lee","year":"2015","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0425","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0430","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1211\/0022357055263","article-title":"The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension","volume":"57","author":"Lennernas","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0435","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1472-6750-8-89","article-title":"Preparation of alginate coated chitosan microparticles for vaccine delivery","volume":"8","author":"Li","year":"2008","journal-title":"BMC Biotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0445","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/S0142-9612(03)00213-8","article-title":"Pectin-based systems for colon-specific drug delivery via oral route","volume":"24","author":"Liu","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0450","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejpb.2004.03.031","article-title":"Drug delivery of oligonucleotides by peptides","volume":"58","author":"Lochmann","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0455","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1021\/bc0603079","article-title":"Role of sulfhydryl groups in transfection? A case study with chitosan-NAC nanoparticles","volume":"18","author":"Loretz","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0460","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0169-409X(93)90010-2","article-title":"The effect of gastro-intestinal mucus on drug absorption","volume":"11","author":"MacAdam","year":"1993","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0465","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0470","doi-asserted-by":"crossref","first-page":"19639","DOI":"10.1039\/c2jm33860b","article-title":"A unique polymeric nano-carrier for anti-tuberculosis therapy","volume":"22","author":"Mane","year":"2012","journal-title":"J. Mater. Chem."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0475","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2008.05.012","article-title":"Gut instincts: explorations in intestinal physiology and drug delivery","volume":"364","author":"McConnell","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0480","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1099\/00221287-148-10-2937","article-title":"Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes","volume":"148","author":"McLean","year":"2002","journal-title":"Microbiology"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0485","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2014.05.038","article-title":"Respirable nanocarriers as a promising strategy for antitubercular drug delivery","volume":"187","author":"Mehanna","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0490","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/AAC.40.8.1893","article-title":"Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection","volume":"40","author":"Mehta","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0495","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/AAC.39.11.2484","article-title":"Biogenesis of the mycobacterial cell wall and the site of action of ethambutol","volume":"39","author":"Mikusova","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0500","doi-asserted-by":"crossref","first-page":"12875","DOI":"10.1021\/bi980096y","article-title":"Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes","volume":"37","author":"Miller","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0505","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1096\/fj.04-2747rev","article-title":"Nanomedicine: current status and future prospects","volume":"19","author":"Moghimi","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0510","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2217\/nnm.13.154","article-title":"Rifampicin-loaded \u2018flower-like\u2019 polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid","volume":"9","author":"Moretton","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0515","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004622","article-title":"Model answers to lipid membrane questions","volume":"3","author":"Mouritsen","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0520","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune system","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0525","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1080\/03639040802130061","article-title":"Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery","volume":"34","author":"Muchow","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","article-title":"State of the art of nanocrystals\u2014special features, production, nanotoxicology aspects and intracellular delivery","volume":"78","author":"Muller","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0535","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbiotec.2004.06.007","article-title":"Challenges and solutions for the delivery of biotech drugs\u2014a review of drug nanocrystal technology and lipid nanoparticles","volume":"113","author":"Muller","year":"2004","journal-title":"J. Biotechnol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0540","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u00a0\u00b1\u00a0a review of the state of the art","volume":"50","author":"Muller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0545","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"Muller","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0550","first-page":"1256","article-title":"Formulation and evaluation of solid lipid nanoparticles of water soluble drug: isoniazid","volume":"3","author":"Nair","year":"2011","journal-title":"Pharm. Sci. Res."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0555","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2015.11.003","article-title":"Mucoadhesive vs. mucopenetrating particulate drug delivery","volume":"98","author":"Netsomboon","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0560","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0565","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1440-1843.2009.01673.x","article-title":"Stopping tuberculosis in the 21st century: goals and strategies","volume":"15","author":"Onozaki","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0570","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2011.10.048","article-title":"Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: in vitro and in vivo evaluation","volume":"422","author":"Paliwal","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0575","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/dkh139","article-title":"Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers","volume":"53","author":"Pandey","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0580","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","article-title":"Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0585","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkl128","article-title":"Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model","volume":"57","author":"Pandey","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0590","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000110009","article-title":"Nanoparticle-based oral drug delivery system for an injectable antibiotic\u2014streptomycin. Evaluation in a murine tuberculosis model","volume":"53","author":"Pandey","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0595","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tube.2005.08.009","article-title":"Oral solid lipid nanoparticle-based antitubercular chemotherapy","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0600","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/10717540500398076","article-title":"Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs","volume":"13","author":"Pandey","year":"2006","journal-title":"Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0605","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tube.2003.07.001","article-title":"Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis","volume":"83","author":"Pandey","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0610","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0615","doi-asserted-by":"crossref","first-page":"370938","DOI":"10.1155\/2013\/370938","article-title":"Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment","volume":"2013","author":"Patel","year":"2013","journal-title":"J. Drug. Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0620","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2014.09.031","article-title":"Targeting of gastrointestinal tract for amended delivery of protein\/peptide therapeutics: strategies and industrial perspectives","volume":"196","author":"Pawar","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0625","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2016.01.041","article-title":"The potential of protein-nanomaterial interaction for advanced drug delivery","volume":"225","author":"Peng","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0630","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijpharm.2014.12.009","article-title":"Pulmonary drug delivery systems for tuberculosis treatment","volume":"478","author":"Pham","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0635","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2217\/nnm.11.122","article-title":"Liposomes as drug delivery systems for the treatment of TB","volume":"6","author":"Pinheiro","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0640","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jconrel.2003.11.013","article-title":"Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs","volume":"95","author":"Prabakaran","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0645","first-page":"398","article-title":"Kinetics and drug release studies of isoniazid encapsulated with PLA-CO- PEG\/gold nanoparticles","volume":"4","author":"Raj","year":"2012","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0650","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","article-title":"Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection","volume":"386","author":"Rangaka","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0655","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0660","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0665","first-page":"88","article-title":"Design and evaluation of controlled release chitosan-calcium alginate microcapsules of anti tubercular drugs for oral use","volume":"2","author":"Sabitha","year":"2010","journal-title":"Int. J. ChemTech Res."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0670","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0675","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0031-6997(25)06622-0","article-title":"Metabolism of foreign compounds by gastrointestinal microorganimsms","volume":"25","author":"Scheline","year":"1973","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0680","doi-asserted-by":"crossref","first-page":"750891","DOI":"10.1155\/2012\/750891","article-title":"Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery","volume":"2012","author":"Severino","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-10711-0_1","article-title":"Lipid nanoparticles\u2014production, characterization and stability","author":"Shah","year":"2015","journal-title":"Pharm. Sci. Drug Dev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0690","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138920013804545133","article-title":"Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication","volume":"14","author":"Shahbazi","year":"2013","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0695","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ijantimicag.2004.07.010","article-title":"Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis","volume":"24","author":"Sharma","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0700","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkh411","article-title":"Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral\/aerosolized antitubercular drug carriers for treatment of tuberculosis","volume":"54","author":"Sharma","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0705","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.msec.2015.08.062","article-title":"Synthesis and characterization of the antitubercular phenazine lapazine and development of PLGA and PCL nanoparticles for its entrapment","volume":"58","author":"Silveira","year":"2016","journal-title":"Mater. Sci. Eng."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0710","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0715","doi-asserted-by":"crossref","first-page":"L1131","DOI":"10.1152\/ajplung.00085.2009","article-title":"Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: dependence on Na+ and Cl\u2212 channel function","volume":"297","author":"Song","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0720","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","article-title":"New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery","volume":"62","author":"Sosnik","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0725","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","article-title":"Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review","volume":"39","author":"Sosnik","year":"2014","journal-title":"Progr. Polym. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0730","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0022-2275(20)36719-5","article-title":"Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis","volume":"16","author":"Takayama","year":"1975","journal-title":"J. Lipid Res."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0735","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.2.1.29","article-title":"Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis","volume":"2","author":"Takayama","year":"1972","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0740","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2013.06.008","article-title":"New perspectives in nanomedicine","volume":"140","author":"Thorley","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0745","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1081\/DDC-120003853","article-title":"Alginate in drug delivery systems","volume":"28","author":"Tonnesen","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0750","first-page":"600","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0755","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"Biodrugs"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0760","first-page":"1","article-title":"Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish","author":"Vibe","year":"2015","journal-title":"Nanotoxicology"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0765","first-page":"255","article-title":"Advancing host-directed therapy for tuberculosis","volume":"15","author":"Wallis","year":"2015","journal-title":"Nat. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0770","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0775","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0378-5173(00)00567-6","article-title":"Amoxycillin release from a floating dosage form based on alginates","volume":"210","author":"Whitehead","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0780","unstructured":"WHO, 2015. Global Tuberculosis Report. WHO Library Cataloguing-in-Publication Data."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0785","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00408-011-9360-x","article-title":"Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery","volume":"190","author":"Willis","year":"2012","journal-title":"Lung"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0790","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1099\/00221287-63-1-41","article-title":"Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis","volume":"63","author":"Winder","year":"1970","journal-title":"J. Gen. Microbiol."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0795","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/CMR.00124-14","article-title":"A microbiological revolution meets an ancient disease: improving the management of tuberculosis with genomics","volume":"28","author":"Wlodarska","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0800","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/jps.20100","article-title":"Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers","volume":"93","author":"Wong","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0805","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2006.09.007","article-title":"Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer","volume":"116","author":"Wong","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0810","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1124\/jpet.106.101154","article-title":"A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system","volume":"317","author":"Wong","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0815","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tube.2015.11.005","article-title":"Systematic review: comparison of Xpert MTB\/RIF, LAMP and SAT methods for the diagnosis of pulmonary tuberculosis","volume":"96","author":"Yan","year":"2016","journal-title":"Tuberculosis (Edinburgh)"},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0820","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.46.6.1875-1879.2002","article-title":"Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis","volume":"46","author":"Yoshimatsu","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0825","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.addr.2012.10.007","article-title":"Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery","volume":"65","author":"Yun","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0830","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0835","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-2600(15)00063-6","article-title":"Tuberculosis treatment and management\u2014an update on treatment regimens, trials, new drugs, and adjunct therapies","volume":"3","author":"Zumla","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/B978-0-323-52725-5.00016-2_bib0840","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323527255000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323527255000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T14:34:48Z","timestamp":1750257288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323527255000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780323527255"],"references-count":167,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-52725-5.00016-2","relation":{},"subject":[],"published":{"date-parts":[[2017]]}}}